ARRAY BIOPHARMA INC's ticker is ARRY and the CUSIP is 04269X105. A total of 215 filers reported holding ARRAY BIOPHARMA INC in Q3 2018. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2019 | $4,898,000 | +41.4% | 105,726 | -40.9% | 0.01% | +150.0% |
Q1 2019 | $3,465,000 | +175.4% | 178,763 | +102.6% | 0.00% | 0.0% |
Q4 2018 | $1,258,000 | -6.2% | 88,256 | 0.0% | 0.00% | 0.0% |
Q3 2018 | $1,341,000 | -33.7% | 88,256 | -26.8% | 0.00% | -33.3% |
Q2 2018 | $2,023,000 | -21.6% | 120,576 | -23.8% | 0.00% | 0.0% |
Q1 2018 | $2,582,000 | +25.0% | 158,223 | -2.0% | 0.00% | 0.0% |
Q4 2017 | $2,066,000 | +25.2% | 161,433 | +20.3% | 0.00% | +50.0% |
Q3 2017 | $1,650,000 | +46.9% | 134,180 | 0.0% | 0.00% | 0.0% |
Q2 2017 | $1,123,000 | +61.1% | 134,180 | +72.0% | 0.00% | +100.0% |
Q1 2017 | $697,000 | +20.8% | 78,014 | +18.8% | 0.00% | 0.0% |
Q4 2016 | $577,000 | -37.1% | 65,693 | -51.7% | 0.00% | -50.0% |
Q3 2016 | $917,000 | +80.9% | 135,895 | +0.1% | 0.00% | +100.0% |
Q2 2016 | $507,000 | +17.9% | 135,695 | 0.0% | 0.00% | 0.0% |
Q1 2016 | $430,000 | -25.0% | 135,695 | 0.0% | 0.00% | 0.0% |
Q4 2015 | $573,000 | -7.4% | 135,695 | 0.0% | 0.00% | 0.0% |
Q3 2015 | $619,000 | – | 135,695 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Redmile Group, LLC | 16,618,776 | $146,079,000 | 12.59% |
BVF INC/IL | 4,986,186 | $43,829,000 | 8.81% |
First Light Asset Management, LLC | 1,000,361 | $8,793,000 | 3.86% |
Crosspoint Capital Strategies, LLC | 463,005 | $4,070,000 | 3.62% |
Consonance Capital Management LP | 2,723,471 | $23,912,000 | 2.63% |
KOPP INVESTMENT ADVISORS LLC | 219,926 | $1,933,000 | 2.04% |
SPHERA FUNDS MANAGEMENT LTD. | 900,000 | $7,911,000 | 2.00% |
Orbimed Advisors | 16,088,800 | $141,421,000 | 1.80% |
Cormorant Asset Management, LP | 1,150,000 | $10,109,000 | 1.36% |
BOGLE INVESTMENT MANAGEMENT L P /DE/ | 2,073,680 | $18,227,000 | 1.26% |